Stanley J - Search Results

1

Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma.

Finke JH, Zea AH, Stanley J, Longo DL, Mizoguchi H, Tubbs RR, Wiltrout RH, O'Shea JJ, Kudoh S, Klein E, et al. Finke JH, et al. Among authors: stanley j. Cancer Res. 1993 Dec 1;53(23):5613-6. Cancer Res. 1993. PMID: 8242613

2

Characterization of a human renal cell carcinoma specific cytotoxic CD8+ T cell line.

Finke JH, Rayman P, Edinger M, Tubbs RR, Stanley J, Klein E, Bukowski R. Finke JH, et al. Among authors: stanley j. J Immunother (1991). 1992 Jan;11(1):1-11. doi: 10.1097/00002371-199201000-00001. J Immunother (1991). 1992. PMID: 1734943

3

Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level.

Chikkala NF, Lewis I, Ulchaker J, Stanley J, Tubbs R, Finke JH. Chikkala NF, et al. Among authors: stanley j. Cancer Res. 1990 Feb 15;50(4):1176-82. Cancer Res. 1990. PMID: 2297766

4

T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present.

Wang Q, Stanley J, Kudoh S, Myles J, Kolenko V, Yi T, Tubbs R, Bukowski R, Finke J. Wang Q, et al. Among authors: stanley j. J Immunol. 1995 Aug 1;155(3):1382-92. J Immunol. 1995. PMID: 7636203

5

T lymphocytes infiltrating renal cell carcinoma have a reduced expression of transferrin receptor.

Kudoh S, Stanley J, Edinger MG, Tubbs RR, Klein E, Bukowski RM, Finke JH. Kudoh S, et al. Among authors: stanley j. Int J Cancer. 1994 Aug 1;58(3):369-75. doi: 10.1002/ijc.2910580311. Int J Cancer. 1994. PMID: 8050820

6

Interleukin 7 enhances the proliferation and effector function of tumor-infiltrating lymphocytes from renal-cell carcinoma.

Sica D, Rayman P, Stanley J, Edinger M, Tubbs RR, Klein E, Bukowski R, Finke JH. Sica D, et al. Among authors: stanley j. Int J Cancer. 1993 Apr 1;53(6):941-7. doi: 10.1002/ijc.2910530613. Int J Cancer. 1993. PMID: 8473051

7

Immunomodulatory effects of interleukin-2 and interleukin-4 in patients with malignancy.

Olencki T, Finke J, Tubbs R, Tuason L, Greene T, McLain D, Swanson SJ, Herzog P, Stanley J, Edinger M, Budd GT, Bukowski RM. Olencki T, et al. Among authors: stanley j. J Immunother Emphasis Tumor Immunol. 1996 Jan;19(1):69-80. doi: 10.1097/00002371-199601000-00008. J Immunother Emphasis Tumor Immunol. 1996. PMID: 8859726 Clinical Trial.

8

Phase I trial of continuous infusion interleukin-2 and doxorubicin in patients with refractory malignancies.

Bukowski RM, Sergi JS, Budd GT, Murthy S, Tubbs R, Gibson V, Bauer L, Stanley J, Gautam S, Finke J. Bukowski RM, et al. Among authors: stanley j. J Immunother (1991). 1991 Dec;10(6):432-9. doi: 10.1097/00002371-199112000-00007. J Immunother (1991). 1991. PMID: 1768677

9

Phase I trial of cisplatin, WR-2721, and the murine monoclonal antibody R24 in patients with metastatic melanoma: clinical and biologic effects.

Bukowski RM, Murthy SA, Finke J, Caulfield MJ, Tubbs R, Herzog P, Stanley J, Edinger M, Tuason L, McLain D, et al. Bukowski RM, et al. Among authors: stanley j. J Immunother Emphasis Tumor Immunol. 1994 May;15(4):273-82. doi: 10.1097/00002371-199405000-00006. J Immunother Emphasis Tumor Immunol. 1994. PMID: 8061900 Clinical Trial.

10

Sankofa: Learning From the Past to Build the Future-Introduction to the Special Issue on Aging in Sub-Saharan Africa.

Stanley JT, Chukwuorji JC. Stanley JT, et al. Innov Aging. 2024 Apr 16;8(4):igae031. doi: 10.1093/geroni/igae031. eCollection 2024. Innov Aging. 2024. PMID: 38628824 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,002 results

Search Page